Search

Displaying results 3251 - 3260 of 10000 in total
  1. Drug

    Volixibat

    go.drugbank.com/drugs/DB13914
    Investigational

    According to Shire, the pharmaceutical manufacturer of Volixibat, it has been granted fast track status by the Food and Drug Administration due to promising initial results and a need for therapeutic treatments … the liver have been implicated in its pathogenesis[A32119].

  2. Drug

    Fenpropidin

    go.drugbank.com/drugs/DB12728
    ApprovedWithdrawn

    Fenpropidin has been investigated for the treatment of Hernia.

    Categories: Compounds used in a research, industrial, or household setting
  3. Drug

    SR 140333

    go.drugbank.com/drugs/DB05790
    Experimental

    SR 140333 is tachykinin antagonist which has potential to treat diarrhoea due to food allergy or inflammatory bowel disease.

  4. Drug

    Panitumumab

    go.drugbank.com/drugs/DB01269
    ApprovedInvestigational

    This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.[L17663]

  5. Drug

    Menadione

    go.drugbank.com/drugs/DB00170
    ApprovedNutraceutical

    A synthetic naphthoquinone without the isoprenoid side chain and biological activity, but can be converted to active vitamin K2, menaquinone, after alkylation in vivo.

  6. Drug

    Auranofin

    go.drugbank.com/drugs/DB00995
    ApprovedInvestigational

    Heme oxygenase 1 is an inducible heme-degrading enzyme with anti-inflammatory properties.

    Synonyms: (1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate, 2,3,4,6-Tetra-O-acetyl-1-thio-beta-D-glucopyranosato-S (triethylphosphine)gold
  7. Drug

    Phleum pratense pollen

    go.drugbank.com/drugs/DB10394
    ApprovedInvestigational

    Phleum pratense pollen allergenic extract is used in allergenic testing.

    Mixtures: SLITone ULTRA D. glomerata/ L. perenne/ P. pratense/ P. pratensis/ A. odoratum
  8. Drug

    Etravirine

    go.drugbank.com/drugs/DB06414
    ApprovedInvestigational

    In 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development … On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg.

  9. Drug

    Bleomycin

    go.drugbank.com/drugs/DB00290
    ApprovedInvestigational

    It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.

    Products: BLEOMICINA 15 U VIAL, BLEOLEM 15 IU LIYOFILIZE TOZ
  10. Drug

    Almasilate

    go.drugbank.com/drugs/DB13595
    Approved

    Almasilate is a buffering antacid that has been used in peptic ulcers and dyspepsia. … However its therapeutic efficacy is not comparable to other approved antacids, as it is no more effective in neutralizing acid and binding bile salts than other conventional antacids [A27138].